Sep 30, 2020 / 05:00PM GMT
Karen Andersen - Morningstar Inc., Research Division - Sector Strategist
Hi, everyone. Good morning or good afternoon, and welcome to our session with BioMarin. I'm Karen Andersen, and I cover biotech as a health care strategist at Morningstar. So BioMarin, in case you're not familiar, they've built a business with several approved treatments for rare diseases, and they have a growing gene therapy pipeline as well. So we've awarded them a narrow moat rating due to their competitive advantages in their spaces.
And we're joined today by Brian Mueller. So Brian has been at BioMarin for close to 18 years, I think, and is currently serving as the firm's Chief Financial Officer. Traci McCarty is also here. She's VP of Investor Relations. So Brian planned a short presentation. And after that, we can follow up with a few questions until we hit our 45-minute mark. Please feel free to submit questions. You can type them into the platform, and I can incorporate them into the discussion with Brian after the slide. So with that, I'll turn it over to Brian.
Brian R. Mueller -
Biomarin Pharmaceutical Inc at Morningstar Management Behind the Moat Conference (Virtual) Transcript
Sep 30, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers